Recently, Novartis announced that it will invest $300 million in next-generation biotherapeutics
.
The investment is designed to further enhance Novartis' capabilities in early-stage biologics technology development, supporting the company's increasingly complex pipeline with advanced technology infrastructure and high-level capabilities
.
Analysts said that at present, large pharmaceutical companies are paying more and more attention to biologics, many large pharmaceutical companies in the past are very dependent on small molecule drugs, and small molecule drugs have been the main driver of corporate growth, and now, with the expiration of many product patents, these companies are beginning to look for strategies to compensate for the decline in revenue, biologics have become one of
the important areas for pharmaceutical companies.
At present, in addition to multinational pharmaceutical companies, many domestic companies are also increasing their layout in the biomedical industry, and some of them have begun to usher in results
.
News on November 1, Liling Biotech announced that it has recently completed an angel round of financing of tens of millions of yuan, jointly invested
by Mint Angel Fund and Yuansheng Venture Capital.
It is understood that Liling Biologics is committed to the development of individualized TCR-T cell therapy and TCR bispecific antibody drugs
.
The funds obtained in this round are mainly used for the improvement of TCR technology platform, the promotion of related project pipelines and team building
.
On October 27, Concord Kirin announced that mowglizumab (trade name Whelkin) has been approved by the State Food and Drug Administration for the treatment of adult patients with relapsed or refractory Sézary syndrome (SS) or advanced (III.
/IV.
) mycosis fungoides granuloma (MF) who have received systemic therapy in the past, becoming the first biologic
approved in China to target CCR4 for the treatment of SS and MF.
In the same month, WuXi Biologics announced that its Eighth Biologics Plant (DP8) in Hangzhou has completed the first GMP production
.
It is understood that DP8 is designed based on a disposable system, prospectively applies SA25 robotic aseptic biologics filling equipment, and is equipped with two completely isolated filling production lines, as well as a special sterile preparation isolator for the preparation of aluminium adjuvant vaccines, which can flexibly provide preparation filling services
for different specifications of vials (2R to 20R) and prefilled needles (1mL to 3mL, long and ordinary type).
This production marks that WuXi Biologics has operated 10 biologics manufacturing plants around the world and is continuously improving its formulation filling capacity and scale
.
At present, from an overall point of view, China's key biological products include genetic engineering drugs, the development of active proteins and peptide drugs, the extraction of Chinese herbal medicines and their effective bioactive ingredients, fermentation and production, the development of various vaccines, monoclonal antibodies and enzyme diagnostic and therapeutic reagents, targeted drugs, etc
.
The strong market demand for these types of drugs will also drive the rapid development
of the industry.
It is worth mentioning that in order to further promote the high-quality development of biomedicine, the state and many places have issued relevant favorable measures
.
For example, the "14th Five-Year Plan" for the development of the bioeconomy proposes to build a bioeconomy pilot zone with cities as the carrier in the Beijing-Tianjin-Hebei, Yangtze River Delta, Guangdong-Hong Kong-Macao Greater Bay Area, Chengdu-Chongqing Economic Circle and other regions, and carry out scientific and technological innovation and reform pilots around the fields of biomedicine, bioagriculture, bioenergy, and bioenvironmental protection, so as to promote the development and growth
of China's bioeconomy.
In addition, the Measures of the Guangdong-Macao Intensive Cooperation Zone in Hengqin to Support the High-quality Development of the Biomedical Health Industry were officially launched on 31 October.
Jinan issued Several Policies and Measures on Accelerating the High-quality Development of Biomedicine and Big Health Industry, launched 17 measures in 5 aspects, and upgraded the original industrial support policies.
.
.
In the future, under the influence of these favorable policies, the industry expects that domestic pharmaceutical companies will usher in more opportunities in the field of biomedicine, and the ability of biomedical innovation will continue to improve
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
